Skip to main content
Fig. 4 | BMC Pulmonary Medicine

Fig. 4

From: Thoracic perfusion of recombinant mutant human tumor necrosis factor (rmhTNF) can be considered as a good adjunct in the treatment of malignant pleural effusion caused by lung cancer

Fig. 4

Safety evaluation of rmhTNF combined with cisplatin versus cisplatin alone through thoracic perfusion for treating MPE. a Combination of rmhTNF and cisplatin does not increase incidence of myelosuppression compared with cisplatin alone. b Combination of rmhTNF and cisplatin decreases the incidence of gastrointestinal side reaction compared with cisplatin alone. c Combination of rmhTNF and cisplatin does not increase the incidence of liver and kidney dysfunction compared with cisplatin alone. rmhTNF, recombinant mutant human tumor necrosis factor injection; MPE, malignant pleural effusion; OR, odds ratio

Back to article page

BMC Pulmonary Medicine

ISSN: 1471-2466

Contact us